Abstract:

The objective of this study was to compare the effectiveness of Efavirenz and Nevirapine based First-line HIV treatment in patients attending comprehensive care centre in Mombasa. This was a prospective comparative study. The target population was HIV positive adult patients eligible for HAART. A total of 251 patients were enrolled in the study and followed up for 12 months. All ARV naive patients with CD4 count < 350/ul with WHO stage 3 or 4 and eligible for HAART were randomly into Efavirenz and Nevirapine based regimens (D4T/3TC/EFV and D4T/3TC/NVP) and followed up for a period of twelve months. Laboratory tests were done for each patient every three months by testing for Haemoglobin, Liver enzyme test (ALT), Creatinine and CD4 cell count. The study showed that first-line regimens of Efavirenz and Nevirapine were effective in suppressing HIV/AIDS infection with improvement in CD4 count (P<0.05). There was also improvement in haemoglobin levels and body weight among the patients on both regimens in the study. However, elevation of ALT and Creatinine were noted in both treatment groups, but this did not warrant drug discontinuation (P>0.05). Efavirenz based regimen appeared to be superior to Nevirapine based regimen on CD4+ profiles and renal function (P<0.05). There was no significant difference in haemoglobin levels, body weight and ALT enzyme for patients on both treatment groups.The findings demonstrated that D4TC/3TC/EFV and D4TC/3TC/NVP combinations were safe, well tolerated and effective in suppressing HIV progression in advanced HIV infected patients.

References:

[1].               Achkar, J. M. and Elizabeth, R. J. (2011). Incipient and Subclinical tuberculosis. Defining early disease states in the context of Host immune response. Journal of Infectious Diseases 204:1179 – 1186.

[2].               Adikwu, E. and Brambija, N. (2013). Concentration effect, incidence and mechanism of Nevirapine hepatotoxicity. American Journal of Pharmacology and Toxicology 8:20-30.

[3].               Banerjee, T., Pensi, T., and Grover, G. (2010). Impact of HAART on survival, weight gain and resting energy expenditure in HIV-1 infected children in India. Annals of Tropical Pediatrics 30: 27-37.

[4].               Chauhan, N. K., Vajpayee, M. and Singh, A. (2011). Usefulness of hemoglobin and albumin as prognostic markers for highly active antiretroviral therapy for HIV- 1 infection. Indian Journal of Medical Sciences 65:286 – 296.

[5].               Denue, B. A., Ikunaiye, P. N. Y. and Denue, C. B. A. (2013). Body mass index changes during highly active antiretroviral therapy in Nigeria. Eastern Mediterranean Health Journal 19:89-97.

[6].               Emily, L. H., Mary, L. T., Kenneth, S., Amy, C. and Melissa, D.J. (2010). Incidence of severe hepatotoxicity related to antiretroviral therapy in HIV/HCV coinfected patients. Aids Research and Treatment. Accessed online at http://dx.doi.org/10.1155/2010/856542.

[7].               Florence, M., Jean, B. G., Joshua, M., Doris, D. and Jan, P. (2011). Anaemia in Human immunodeficiency virus infected and uninfected women in Rwanda. American Journal of Tropical Medicine and Hygiene 84: 456 – 460

[8].               Kalyesubula, R., Kagimu, M., Opio, K., Kiguba, R., Semitala, C., Schlech, W. and Katabira, E. (2011). Hepatotoxicity from first line antiretroviral therapy: an experience from a resource limited setting. Journal of African Health Sciences, 11: 16-23.

[9].               Kenya AIDS Progress Report. (2014). Kenya Demograhic Health Survey. (2014).

[10].            Kenya National Bureau of Statistics. (2009) Population and Housing Census, Pg. 7.

[11].            Kenneth, A. A., Olumuyiwa, O., Dorothy, A., Tindak, S., Mohamed, A., Stephen, O., Rosalyn, C. K. and Anthony, K. W. (2013). Medication adherence and cluster of differenciation for CD4 Cells response in patients receiving antiretroviral therapy. Journal of AIDS and HIV Research 5:163-169.

[12].            Lifson, A. R., Krautz, E. M., Eberly, L. E., Dolan, M. J., Marconi, V. C., Weintrob, A. C., Cianflora, N. F., Ganesan, A., Grambsch, P. L. and Agan, B. K. (2011). Long term CD4 lymphocyte response following HAART initiation in a US military prospective cohort. Journal of AIDS Research and Therapy 8:2 http://www.aidsrestherapy.com.

[13].            Lucien, K. F., Clement, A. N. J., Fon, N. P., Weledji, P. and Ndikvu, C. P. (2010). The Effects of antiretroviral therapy treatment on liver function enzymes among HIV infected out patients attending the Central Hospital of Yaounde Cameroon. African Journal of Clinical and Experimental Microbiology 11:3.

[14].            Mainasara, A. S., Isah, B. A., Ahmed, A. Y. and Erhabor, O. (2014). Effect of highly active antiretroviral therapy (HAART) on renal functions among persons living with HIV and AIDS (PLWHA) in Sokoto, North Western Nigeria. American Journal of Pharmacy and Pharmacology 13: 23 – 27.

[15].            Paolo, M., Dario, B., Paolo, B., Leonardo, C., Chiara, C., Antonio, D. B., Simone, M., Francesco, M., Vincenzo, M., Cristina, M., Pasquale, N., Stefano, R. and Fabio, V. (2012). Renal complications in HIV disease: Between present and future. AIDS Research 14: 37 – 53.

[16].            Robert, A. N., David, O. and George, A. (2015). Effects of HIV infection and Highly Active Antiretroviral Therapy (HAART) on the Liver of HIV patients. Trends in Medical Research 10: 1-11.

[17].            Shakirat, I. B., Abel, N. O. and Patrick, O. E. (2014). Long term effect of HAART on biochemical profiles of HIV/AIDS patients in a tertiary health facility in Benin city, Nigeria. Tropical Journal of Pharmaceutical Research 11:1941 – 1946.

[18].            Simbarashe, T., Mhairi, M., Alana, T. B., Ian, S., Patrick, M. and Mathew, P. F. (2013). Anaemia among HIV infected patients initiating antiretroviral therapy in South Africa: Improvement in hemoglobin regardless of degree of immunosuppression and the initiating ART regimen. Journal of Tropical Medicine 27:162950. Epub 2013 Aug 27 http://dx.doi.org/10.1155/2013/162950.

[19].            World Health Organization. AIDS Epidemic Update. (2015).

[20].            World Health Organization (WHO) (2007). Addendum to 2006 WHO guidelines on Antiretroviral Therapy for HIV Infection in Adults and adolescents Geneva.

[21].            Zelalem, T. and Bamlaku, E. (2014). Prevalence of anaemia before and after initiation of highly active antiretroviral therapy among HIV positive patients in North West Ethiopia: A retrospective study. BMC Research Notes 7:745.